Vertical: CNMBase Year: 2025
Market Size (2025)
$179.84M
Projected (2032)
$344.93M
CAGR (2022–2032)
9.8%
Key Players
7+
Market Overview
The global Bacillus firmus market was valued at USD 179.84 Million in 2025 and is projected to reach USD 344.93 Million by 2032, registering a CAGR of 9.74% over the 2026–2032 forecast period. The market expanded from USD 135.50 Million in 2022 to USD 163.68 Million in 2024, and is expected to add USD 165.09 Million in absolute value between 2025 and 2032.
Bacillus firmus is a spore-forming, Gram-positive soil bacterium used as the active ingredient in biological nematicides. Commercial products, most notably those based on strain I-1582, are applied to soil or to seed to protect plant roots against plant-parasitic nematodes such as root-knot (Meloidogyne spp.), cyst (Heterodera spp.), lesion (Pratylenchus spp.) and reniform (Rotylenchulus spp.) nematodes. Demand is shaped by the progressive withdrawal and restriction of conventional chemical nematicides, the growth of residue-sensitive fruit and vegetable production, the expansion of biological seed treatment in row crops, and public policy that favours biological inputs.
Key Findings
Formulation: Wettable Powder is the largest formulation, at USD 89.92 Million in 2025 (50.0% share). Liquid is the fastest-growing formulation, with a CAGR of 11.69%.
Crop Type: Fruits & Vegetables is the largest crop type, at USD 107.90 Million in 2025 (60.0% share). Cereals & Grains is the fastest-growing crop type, with a CAGR of 10.54%.
Application Method: Soil Treatment is the larger application method, at USD 134.88 Million in 2025 (75.0% share). Seed Treatment is the faster-growing method, with a CAGR of 11.60%.
Region: North America is the leading region, at USD 59.35 Million in 2025 (33.0% share). Middle East & Africa is the fastest-growing region, with a CAGR of 11.79%, followed by Asia Pacific at 11.46%.
Country: The U.S. is the leading country market, at USD 46.29 Million in 2025. India is the fastest-growing country market, with a CAGR of 13.37%.
Segmentation Summary
The market is analysed by formulation (Wettable Powder, Liquid and Granules), crop type (Fruits & Vegetables, Cereals & Grains and Others), application method (Soil Treatment and Seed Treatment) and region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa), with 20 country and sub-regional markets. Wettable Powder retains the largest share because of its long shelf life and established use in soil-applied programmes, while Liquid formulations grow faster on the back of on-seed and drip-irrigation application. Fruits & Vegetables dominates demand because high-value horticultural crops face the heaviest nematode pressure and the strictest residue requirements. Soil Treatment remains the core application method, but Seed Treatment is gaining share as biological nematicides are combined with insecticide and fungicide seed-treatment packages in corn, soybean and cotton.
Competitive Landscape Summary
The market is consolidated at the active-ingredient level and fragmented at the regional level. Strain I-1582, originally developed by AgroGreen (Minrav Group, Israel) and later commercialised by Bayer, underpins the largest branded portfolio. Since August 2018 the VOTiVO seed-treatment line has belonged to BASF SE, which sells B. firmus I-1582 as VOTiVO 240 FS and in the Poncho VOTiVO combination products in the United States and Canada, and as Votivo Prime, Andril Prime and Oleaje Prime in Brazil. BioFirst Group, through its Brazilian unit Biotrop, markets products based on a separate B. firmus isolate (Good-Win). Bayer AG, which built the original I-1582 business, remains an influential participant in biological nematicides through its partnerships and distribution agreements, while Envu serves the turf segment and regional suppliers in India and China serve price-sensitive horticultural markets. Competition centres on field efficacy, registration coverage, compatibility with seed-treatment packages and access to distribution through seed companies and agro-input retailers.
Challenges and Opportunities
The main challenges are regulatory. The European Union approval of B. firmus I-1582 under Regulation (EC) No 1107/2009 ran from 1 October 2013 to 30 September 2023 and was not renewed, which constrains product availability in EU member states. Biological nematicides also face variable field performance under differing soil temperatures, moisture levels and nematode densities, together with competition from other microbial nematicides and from newer synthetic nematicides. Opportunities arise from the phase-out of older chemical nematicides, such as the EU non-renewal of oxamyl in 2023 and California's 2024 regulation of 1,3-dichloropropene, from Brazil's Bioinputs Law (Law No. 15,070 of December 2024), and from untapped registration potential in Asia Pacific and the Middle East & Africa, where growth rates are the highest.
Future Outlook
The market is expected to grow steadily, with value nearly doubling between 2025 and 2032. Growth will be led by Liquid formulations, Seed Treatment and the Cereals & Grains crop segment, and geographically by the Middle East & Africa and Asia Pacific, while North America will remain the largest regional market throughout the forecast period at USD 107.06 Million in 2032. Companies that combine registration breadth, seed-treatment partnerships and robust formulation technology are positioned to capture a disproportionate share of incremental demand.
The Bacillus Firmus Market market is projected to grow at a CAGR of 9.8% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDefinition
Bacillus firmus is an aerobic, Gram-positive, endospore-forming bacterium naturally present in soil. Selected strains, of which I-1582 is the most widely registered, are produced by fermentation and formulated as biological nematicides. After application to soil or seed, the bacterium colonises the rhizosphere and the root surface, where it reduces nematode infection through the production of enzymes and metabolites that degrade nematode eggs and juveniles, and through competition for root-colonisation sites. The US Environmental Protection Agency first registered B. firmus strain I-1582 as a biopesticide active ingredient in 2008.
For the purpose of this study, the market includes the value of commercial crop-protection products in which Bacillus firmus is a declared active ingredient, sold either as stand-alone biological nematicides or as part of co-formulated or co-packaged seed-treatment products, in wettable powder, liquid and granule formulations, for soil and seed application. The market excludes products based on other Bacillus species (such as B. subtilis, B. amyloliquefaciens or B. velezensis), fungal nematicides (such as Purpureocillium lilacinum and Pochonia chlamydosporia), botanical nematicides, synthetic chemical nematicides, and the value of the non-B. firmus active ingredients in combination products. Unregistered on-farm multiplication of microbial cultures is also excluded.
Scope of the Study
The study covers the global Bacillus firmus market, segmented as follows:
By Formulation: Wettable Powder, Liquid and Granules.
By Crop Type: Fruits & Vegetables, Cereals & Grains and Others. The Others segment covers crops outside the first two categories, including oilseeds and pulses, fibre and industrial crops, turf and ornamentals.
By Application Method: Soil Treatment and Seed Treatment.
By Region: North America (U.S., Canada, Mexico); Europe (Germany, U.K., France, Italy, Spain, Rest of Europe); Asia Pacific (China, India, Japan, Rest of Asia Pacific); Latin America (Brazil, Argentina, Rest of Latin America); and Middle East & Africa (UAE, Saudi Arabia, South Africa, Rest of MEA).
Timeline: Historic years 2022–2024, base year 2025 and forecast period 2026–2032.
Unit: All values are presented in USD Million.
Research Objectives
To estimate the size of the global Bacillus firmus market for 2022–2024 and 2025, and to forecast it for 2026–2032 in USD Million.
To analyse the market by formulation, crop type and application method, and to identify the largest and fastest-growing segments.
To assess the market across five regions and 20 country and sub-regional markets, and to quantify regional and country growth.
To evaluate the drivers, restraints, opportunities, trends and challenges affecting the adoption of B. firmus-based biological nematicides.
To examine the regulatory frameworks governing the registration and use of microbial nematicides in key regions.
To analyse the value chain, competitive forces and PESTEL factors that shape the market.
To identify the leading companies, assess their competitive positioning and track key developments since 2022.
To provide decision-makers with a quantified outlook for investment, portfolio and market-entry planning.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansOverview of the Research Process
The study follows a structured research process combining secondary research, primary research and analytical modelling. The process starts with defining the market and its segmentation, continues with the collection of qualitative and quantitative information from secondary sources, and is followed by validation through primary interviews with participants across the value chain. Market estimates are developed using both top-down and bottom-up approaches, triangulated, and then projected over the forecast period using a factor-based forecasting model. The final estimates are reviewed for internal consistency across segments, regions and countries.
Secondary Research
Secondary research was used to build an understanding of the product, its regulatory status, its supply base and its demand drivers. Sources relevant to the biological crop-protection industry include:
Regulatory and government bodies: pesticide registration databases and decision documents of the US Environmental Protection Agency, the European Food Safety Authority and the European Commission, Health Canada's Pest Management Regulatory Agency, India's Central Insecticides Board and Registration Committee, Brazil's Ministry of Agriculture and Livestock, China's Institute for the Control of Agrochemicals and the Australian Pesticides and Veterinary Medicines Authority.
Agricultural statistics agencies: crop area, production and agrochemical-use statistics from bodies such as the USDA National Agricultural Statistics Service and the Food and Agriculture Organization of the United Nations.
Industry associations: publications of biological and crop-protection associations, such as the Biological Products Industry Alliance, the International Biocontrol Manufacturers Association and CropLife International.
Company sources: annual reports, investor presentations, product labels, press releases and technical bulletins of manufacturers and distributors.
Trade and scientific literature: trade journals on agribusiness and biologicals, and peer-reviewed nematology and plant-protection research.
Paid databases: trade, company and agrochemical registration databases.
Primary Research
Primary research was conducted to validate secondary findings, fill information gaps and obtain insights on pricing, adoption, product performance and market outlook. Interviews were carried out with respondents from both the supply side and the demand side of the market.
Supply-side respondents: product managers, business development heads and regulatory affairs managers at biological crop-protection manufacturers, seed-treatment formulators, fermentation contract manufacturers and distributors.
Demand-side respondents: growers of horticultural and row crops, seed companies, crop advisers and agronomists, agro-input retailers and researchers at agricultural universities and nematology institutes.
Objectives: to validate market size and segment splits, understand purchase criteria and switching behaviour, assess pricing and margins along the channel, and gauge the expected impact of regulatory changes and new product launches.
Market Size Estimation
Top-down approach: The overall nematicide and biological nematicide markets were assessed by region, and the share attributable to B. firmus-based products was estimated from product registrations, company disclosures and expert inputs. This share was then allocated to formulation, crop type and application method using adoption patterns observed in each region.
Bottom-up approach: Market value was built up from treated crop area, application rates and seed-treatment penetration by crop and country, multiplied by average product prices. Country estimates were aggregated to regional and global totals.
Data triangulation: Results from the two approaches were compared and reconciled. Where differences arose, the estimates were adjusted using primary research inputs, so that segment, country, regional and global figures are internally consistent.
Forecasting Methodology
Forecasts were developed for 2026–2032 using the 2025 base-year estimates and a factor-based approach. The factors considered include crop area and crop-value trends, nematode pressure, the regulatory status of chemical nematicides and of B. firmus in each country, the pace of biological seed-treatment adoption, product pricing, new registrations and launches, and macroeconomic conditions in agriculture. Each factor was weighted according to its expected impact in the short, medium and long term, and the resulting growth rates were validated with industry experts.
Base Year, Forecast Period and Currency
Historic years: 2022, 2023 and 2024.
Base year: 2025.
Forecast period: 2026–2032, with CAGR calculated for 2026–2032.
Currency: USD Million, at constant exchange rates.
Assumptions and Limitations
Exchange rates are assumed to remain stable over the forecast period, and inflation effects are not separately modelled.
The regulatory status of B. firmus and of competing chemical nematicides is assumed to evolve in line with policies announced as of the base year.
No major disruption to agricultural trade or to fermentation supply chains is assumed.
Values relate to the B. firmus component of products sold; in combination products this requires an allocation of value between active ingredients, which introduces estimation uncertainty.
Company-level sales of B. firmus products are rarely disclosed, so company estimates rely on indirect indicators and expert judgement.
Limited public statistics on biological input use in several emerging markets increase the margin of uncertainty for smaller countries.
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The global Bacillus firmus market is consolidated at the level of the active ingredient and fragmented at the regional level. Strain I-1582, originally developed by AgroGreen, part of Israel's Minrav Group, and subsequently acquired and commercialised by Bayer, is the most widely registered strain and underpins the leading branded portfolio. Following Bayer's acquisition of Monsanto, the VOTiVO seed-treatment business was transferred to BASF in August 2018, making BASF the principal global supplier of B. firmus seed-treatment products. Outside this portfolio, the market includes regional companies with their own B. firmus isolates, such as Biotrop in Brazil, and smaller producers in India and China that serve local horticultural markets.
Competition takes place on several levels: between B. firmus products and other biological nematicides; between biological and synthetic nematicides; and, within seed treatment, for inclusion in seed-company treatment packages. Key competitive factors include proven field efficacy, breadth of registrations, compatibility with other seed-treatment components, formulation stability, price and access to distribution. The broader biologicals industry is consolidating, with large crop-protection companies and specialist biological groups expanding through acquisitions and partnerships.
Key Player Positioning
Leaders
BASF SE (Ludwigshafen, Germany) is the market leader. The group reported sales of EUR 59,657 million in 2025, of which its Agricultural Solutions segment accounted for EUR 9,587 million, including EUR 575 million from seed treatment. BASF markets B. firmus I-1582 as VOTiVO 240 FS and in Poncho VOTiVO and Poncho VOTiVO 2.0 (clothianidin plus B. firmus) in the United States, as VOTiVO 240 FS in Canada, and as Votivo Prime, Andril Prime and Oleaje Prime in Brazil. In October 2023 it launched Poncho VOTiVO Precise for soybean. BASF's strategy centres on biological nematode protection delivered through seed treatment for corn, soybean and cotton, sold through seed companies and its own seed brands.
Challengers
BioFirst Group (Westerlo, Belgium), formerly Biobest Group, is a fast-growing biologicals company with units including Biobest, BioWorks, Plant Products and Biotrop. It does not publish standalone revenue; the Life Sciences division of its parent, Floridienne, which includes BioFirst, reported revenue of EUR 538.3 million for 2025. Through Biotrop, it markets B. firmus-based products in Brazil, including Good-Win, targeting Meloidogyne incognita and Pratylenchus brachyurus. Its strategy is to combine its horticultural biocontrol base with open-field row-crop biologicals in Brazil.
Bayer AG (Leverkusen, Germany) built the original B. firmus I-1582 business, including the BioNem, VOTiVO and Flocter brands, and continues to shape the biological nematicide segment. The group reported sales of EUR 45.575 billion in 2025, including EUR 21.622 billion from Crop Science. Bayer's biologicals strategy relies on partnerships and licensing, including agreements with Ginkgo Bioworks, Kimitec and AlphaBio Control, and a 2025 distribution agreement for Ecospray's garlic-based bionematicide in Europe, the Middle East and parts of Africa.
Niche Players
Envu (Cary, United States), formed from Bayer's former Environmental Science Professional business in 2022, serves non-crop markets such as turf and ornamentals, where B. firmus I-1582 was marketed for nematode control on turf. Its revenue is not publicly disclosed.
AgriLife (India) Pvt Ltd (Hyderabad, India) is a manufacturer of biopesticides, biofertilisers and biostimulants that markets a B. firmus nematicide (Bionemagon) for soil application. Jiangxi Shunquan Biotechnology Co., Ltd (Fuzhou, China) is a microbial pesticide producer that lists B. firmus among its main Bacillus products. Bactostore (Kolhapur, India) supplies a liquid B. firmus bionematicide for horticultural crops. The revenues of these companies are not publicly disclosed. They compete mainly on price and local distribution in their domestic markets.
Threat of New Entrants – Medium
Registration of a new microbial active ingredient or strain requires significant investment in data generation and time.
Fermentation capacity can be outsourced, which lowers the capital barrier for formulators.
In less regulated markets, small local producers can enter with generic Bacillus formulations.
Bargaining Power of Suppliers – Low
Fermentation media and carriers are widely available commodities.
Contract fermentation capacity is available in most major regions.
Strain ownership is concentrated among product owners rather than independent suppliers.
Bargaining Power of Buyers – Medium
Seed companies and large distributors purchase in volume and can negotiate prices.
Individual growers are fragmented and have limited bargaining power.
Growers can switch to other biological or chemical options if value is not demonstrated.
Threat of Substitutes – High
Other biological nematicides (other Bacillus species, fungal agents, botanicals) target the same pests.
Newer synthetic nematicides offer faster and more consistent control.
Resistant varieties, crop rotation and soil management can reduce the need for treatment.
Competitive Rivalry – Medium
The number of companies with registered B. firmus products is limited.
Competition is more intense in the wider biological nematicide category.
Differentiation relies on efficacy data, combination products and channel access.
Threat of New Entrants: Medium; Registration costs offset by outsourced fermentation.
Bargaining Power of Suppliers: Low; Commodity inputs and available contract capacity.
Bargaining Power of Buyers: Medium; Concentrated seed-company and distributor demand.
Threat of Substitutes: High; Wide range of biological, chemical and cultural alternatives.
Competitive Rivalry: Medium; Few registered B. firmus suppliers within a crowded biologicals category.
Market estimates by geography (2032)
InsightNorth America leads with $107.06M by 2032, while Asia Pacific is projected to grow fastest at a 11.6% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $45.85M | $70.37M | $107.06M | 8.9% | 31% |
| Europe | $33.13M | $51.41M | $79.16M | 9.1% | 23% |
| Asia Pacific | $23.17M | $40.35M | $69.33M | 11.6% | 20% |
| Latin America | $27.93M | $45.77M | $73.64M | 10.2% | 21% |
| Middle East & Africa | $5.42M | $9.02M | $15.73M | 11.2% | 5% |
| Total | $135.50M | $216.92M | $344.93M | 9.8% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$344.93M
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Wettable Powder | $157.49M | 8.4% | 46% |
| Liquid | $117.24M | 11.8% | 34% |
| Granules | $70.19M | 10.2% | 20% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Bacillus Firmus Market covering market dynamics, competitive landscape, and strategic outlook.
The Bacillus Firmus Market market is projected to reach $344.93M by 2032, growing at 9.8% CAGR. The Wettable Powder segment holds the largest share.
The global Bacillus firmus market is expected to grow from USD 179.84 Million in 2025 to USD 344.93 Million by 2032, at a CAGR of 9.74%. This growth reflects the interaction of regulatory, agronomic and commercial factors. The growth factor analysis in Section 4.2 summarises five macro and five micro factors. The impact scores in the table are analyst assessments on a scale of 1 to 10, where a higher score indicates a stronger influence on the market in the period shown.
Withdrawal and Restriction of Chemical Nematicides
Conventional nematicides, including organophosphates, carbamates and soil fumigants, have come under sustained regulatory pressure because of their toxicity to humans, wildlife and non-target soil organisms. In the European Union, the approval of oxamyl was not renewed under Implementing Regulation (EU) 2023/741, with the non-renewal taking effect in May 2023 and a grace period for the use of existing stocks to November 2023. In the United States, the California Department of Pesticide Regulation brought a new regulation on 1,3-dichloropropene into effect on 1 January 2024, tightening conditions on one of the most widely used soil fumigants. Earlier withdrawals of products such as methyl bromide under the Montreal Protocol had already reduced the chemical options available to growers. As the toolbox of synthetic nematicides narrows, growers of high-value crops and seed companies are turning to biological nematicides that can be used within integrated nematode-management programmes. B. firmus, with a tolerance exemption for food and feed uses in the United States and a favourable worker-safety profile, is well positioned to fill part of this gap, particularly where it can be used alongside crop rotation, resistant varieties and remaining chemical options.
Significant Crop Losses Caused by Plant-Parasitic Nematodes
Plant-parasitic nematodes are among the most damaging and least visible crop pests. A USDA-supported multistate research project (W5186) estimates worldwide crop losses from nematodes at USD 80–157 billion per year, including at least USD 8 billion in the United States, and average annual yield losses of around 10–14% in major crops. Root-knot nematodes affect almost all vegetable crops, soybean cyst nematode is a leading yield-limiting pest of soybean in North America, and lesion nematodes such as Pratylenchus brachyurus are a growing concern in Brazilian soybean and cotton. Symptoms are often mistaken for nutrient deficiency or drought stress, so the spread of soil diagnostics and grower education is raising awareness of the economic damage involved. This increasing recognition of nematode damage expands the treated area for nematicides in general and creates demand for preventive, low-residue tools such as B. firmus, which protect roots during early crop establishment when plants are most vulnerable.
Expansion of Biological Seed Treatment in Row Crops
Seed treatment has become one of the most efficient routes to market for biological nematicides because it places a small quantity of active ingredient where root protection is needed and fits into existing seed-company processes. In the United States and Canada, B. firmus I-1582 is sold as VOTiVO 240 FS and in Poncho VOTiVO combination products for corn, soybean and cotton, and BASF launched Poncho VOTiVO Precise for soybean in October 2023. In Brazil, BASF and Biotrop have registered B. firmus seed-treatment products targeting root-knot and lesion nematodes. Seed companies increasingly offer biological components as part of premium seed-treatment packages, which supports adoption without requiring growers to change their application equipment. This trend is reflected in the market data: Seed Treatment is projected to grow at a CAGR of 11.60%, compared with 9.06% for Soil Treatment.
Policy Support for Biological and Sustainable Inputs
Governments in several major agricultural economies are actively promoting biological inputs. The European Commission's Farm to Fork Strategy set targets to reduce the use and risk of chemical pesticides by 50% and the use of more hazardous pesticides by 50% by 2030, against a 2015–2017 baseline. Brazil adopted Law No. 15,070 of 23 December 2024, which establishes a dedicated legal framework for the production, registration, trade and use of bioinputs, building on the National Bioinputs Programme of the Ministry of Agriculture and Livestock. Japan's MIDORI Strategy for Sustainable Food Systems aims to reduce the risk-weighted use of chemical pesticides by 50% by 2050, and India continues to promote natural and organic farming through national programmes. Such policies create favourable registration pathways, public extension support and growing market access for biological nematicides, including B. firmus-based products.
Combination and Multi-Mode Seed-Treatment Products
Combining B. firmus with insecticides, fungicides, other microbes or biostimulants allows suppliers to offer broader-spectrum protection and to address the variability of single biological agents. The success of clothianidin plus B. firmus seed treatments in North America shows that combination products can achieve wide acreage. Extending this model to new crops, such as cotton, sugar beet, pulses and vegetables, and to new markets in Latin America and Asia Pacific represents a significant opportunity.
Registration Expansion in High-Growth Emerging Markets
Asia Pacific and the Middle East & Africa are the fastest-growing regions, at CAGRs of 11.46% and 11.79%, respectively. Large vegetable and fruit production bases in China and India, protected agriculture in the Gulf states, and export horticulture in North Africa offer substantial headroom. Companies that secure formal registrations in these markets, and invest in local demonstration trials and distributor partnerships, can establish an early position before competition intensifies.
Growth of Bioinputs Frameworks in Latin America
Brazil's Bioinputs Law and its large row-crop area create a favourable environment for biological nematicides, especially in soybean, cotton and sugarcane, where lesion and root-knot nematodes are widespread. Argentina and other countries in the region are also strengthening their frameworks for biological products. These developments open opportunities for registered products, technology licensing and local fermentation partnerships.
Regulatory Fragmentation and Approval Lapses
Registration requirements for microbial pesticides differ widely between countries, and the cost and time of obtaining approvals can be high relative to the size of the market. The clearest example is the European Union, where the approval of B. firmus I-1582, granted by Implementing Regulation (EU) No 366/2013, expired on 30 September 2023 without renewal. In India, B. firmus is not included in the Directorate of Plant Protection, Quarantine & Storage list of major uses of registered bio-insecticides as of 31 March 2024. Such gaps limit the addressable market and leave room for unregistered or poorly characterised products, which can damage grower confidence in the category.
Variable Field Efficacy and Shelf-Life Constraints
As a living organism, B. firmus depends on soil temperature, moisture, organic matter and root growth to establish and act. Its efficacy is generally preventive and partial rather than curative, and results can be inconsistent under high nematode populations or unfavourable conditions. Growers accustomed to the fast, visible action of chemical nematicides may perceive this as a weakness. In addition, maintaining spore viability through storage and distribution, especially in hot climates and in liquid formulations, requires careful formulation and cold-chain or controlled-storage practices, which raises costs.
Competition from Alternative Nematode Control Solutions
B. firmus competes with a growing range of biological nematicides based on other organisms, including other Bacillus species, Purpureocillium lilacinum, Pochonia chlamydosporia and botanical extracts such as garlic-derived products, as well as with newer synthetic nematicides with improved safety profiles. Resistant crop varieties and cultural practices such as rotation further reduce the need for treatments in some crops. This competitive pressure limits pricing power and requires suppliers to demonstrate clear return on investment.
Consolidation in the Biologicals Industry
Large crop-protection companies and specialist biological groups are acquiring or partnering with biological producers to broaden their portfolios. Examples since 2022 include Biobest's acquisitions of BioWorks in the United States and of a majority stake in Biotrop in Brazil, and Bayer's partnerships with Ginkgo Bioworks and Kimitec. This consolidation increases investment in research, registration and distribution, but also raises entry barriers for smaller companies.
Shift towards Liquid Formulations
Liquid formulations are easier to apply on seed and through drip-irrigation systems, and are compatible with modern seed-treatment equipment. Liquid is the fastest-growing formulation, with a CAGR of 11.69% over 2026–2032. The main technical challenge is ensuring spore stability and shelf life in liquid carriers.
Demand for Residue-Free Produce
Retailers and export markets apply increasingly strict maximum residue limits and private standards, which encourages fruit and vegetable growers to adopt biological tools that do not leave chemical residues. This supports the leading position of the Fruits & Vegetables segment.
Need for Grower Education and Demonstration
Because nematode damage is often hidden and biological efficacy is preventive, demonstration trials, soil diagnostics and advisory support remain essential to adoption. Suppliers that invest in agronomic services tend to achieve better retention, while the absence of such support remains a challenge in fragmented smallholder markets.
The value chain of the Bacillus firmus market consists of four main stages, from strain and raw materials to end use.
Raw materials and inputs: Proprietary or licensed B. firmus strains, fermentation media (carbon and nitrogen sources such as sugars, starches and soy or yeast extracts), carriers, surfactants, stabilisers and packaging materials. Strain ownership and characterisation are the key sources of value at this stage.
Manufacturing: Submerged fermentation to high spore counts, followed by recovery, concentration and drying, and formulation into wettable powders, liquid suspension concentrates and granules. Quality control of spore count, purity and shelf life is critical. Production is carried out in-house by large companies or by contract fermentation facilities.
Distribution and channels: Products reach users through seed companies and seed-treatment providers, national and regional agrochemical distributors, agro-input retailers and co-operatives, and increasingly through online channels for smallholders. For seed-treatment products, the seed company often acts as the main customer and channel.
End users: Growers of fruits and vegetables, cereals and grains, oilseeds and pulses, industrial crops, and turf and ornamentals, as well as greenhouse and protected-cultivation operations.
North America
In the United States, B. firmus products are registered by the Environmental Protection Agency under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). B. firmus strain I-1582 was first registered in 2008, and 40 CFR 180.1282 grants an exemption from the requirement of a tolerance for residues of B. firmus I-1582 in or on all food commodities when used as a soil or seed treatment. In Canada, products are regulated by Health Canada's Pest Management Regulatory Agency under the Pest Control Products Act; the agency proposed the registration of B. firmus strain I-1582 and VOTiVO 240 FS in Proposed Registration Decision PRD2011-24. In Mexico, pesticide registration is overseen by the Federal Commission for the Protection against Sanitary Risks (COFEPRIS).
Europe
In the European Union, active substances are approved under Regulation (EC) No 1107/2009 and products are authorised by member states. B. firmus I-1582 was approved by Implementing Regulation (EU) No 366/2013 for the period 1 October 2013 to 30 September 2023; the approval expired without renewal. The European Food Safety Authority published its conclusion on the peer review of the substance before approval. Directive 2009/128/EC on the sustainable use of pesticides requires member states to promote integrated pest management and non-chemical methods. In Great Britain, plant protection products are regulated by the Health and Safety Executive under retained Regulation 1107/2009.
Asia Pacific
In China, pesticides, including microbial pesticides, are registered with the Institute for the Control of Agrochemicals of the Ministry of Agriculture and Rural Affairs (ICAMA) under the Regulations on Pesticide Administration. In India, biopesticides must be registered with the Central Insecticides Board and Registration Committee under the Insecticides Act, 1968. In Japan, agricultural chemicals are registered by the Ministry of Agriculture, Forestry and Fisheries under the Agricultural Chemicals Regulation Act, and in Australia by the Australian Pesticides and Veterinary Medicines Authority under the Agvet Code.
Latin America
In Brazil, pesticide registration is governed by Law No. 14,785 of 2023, with the Ministry of Agriculture and Livestock (MAPA) responsible for registration, and bioinputs are additionally covered by Law No. 15,070 of 2024. In Argentina, plant protection products are registered by the National Agri-Food Health and Quality Service (SENASA).
Middle East & Africa
In South Africa, agricultural remedies are registered under the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act No. 36 of 1947). In the United Arab Emirates, pesticide registration is managed by the Ministry of Climate Change and Environment, and in Saudi Arabia by the Ministry of Environment, Water and Agriculture.
Oct 2022: Bayer AG; Partnership; Closed an agreement with Ginkgo Bioworks, transferring its West Sacramento biologics site and establishing a multi-year partnership in agricultural biologicals.
Oct 2022: Envu; Divestment / Formation; Bayer completed the sale of its Environmental Science Professional business to Cinven, which began operating as Envu.
Feb 2023: Bayer AG; Partnership; Entered a partnership with Kimitec covering biological crop protection and biostimulant solutions.
Jul 2023: Biobest (BioFirst Group); Acquisition; Completed the acquisition of BioWorks, a US biological crop-protection company.
Oct 2023: BASF SE; Product Launch; Launched Poncho VOTiVO Precise, a soybean seed treatment combining a biological nematode barrier with an insecticide.
2023: Biobest (BioFirst Group); Acquisition; Completed the acquisition of a majority stake (approximately 85%) in Biotrop, a Brazilian biologicals company with B. firmus products.
Apr 2024: BioFirst Group; Corporate; Biobest Group renamed itself BioFirst Group, with Biobest, BioWorks, Plant Products and Biotrop as business units.
Apr 2024: Bayer AG; Licensing; Secured exclusive rights to a bioinsecticide from AlphaBio Control.
Nov 2024: Envu; Acquisition; Completed the acquisition of FMC's Global Specialty Solutions business.
Jan 2025: Bayer AG; Distribution Agreement; Signed an exclusive agreement to distribute Ecospray's garlic-based bionematicide in Europe, the Middle East and parts of Africa.
Aug 2025: BASF SE; Regulatory; Received an amended US EPA label for Poncho VOTiVO 2.0 (clothianidin plus B. firmus I-1582).
Oct 2025: BASF SE; Corporate; Announced plans for a partial initial public offering of its Agricultural Solutions division in 2027.
Oct 2026: BioFirst Group; Acquisition; Acquired the remaining stake in Biotrop, taking full ownership.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 106 companies operating in the Bacillus Firmus Market market, including revenue, employee count, and market positioning where available.
Showing 106 of 106 companies
BASF is the world's largest chemical company by sales, built on the Verbund principle of physically and energetically integrated production sites that turn a handful of feedstocks into thousands of products. Since September 2024 it has run under the "Winning Ways" strategy, which splits the portfolio into four core segments (Chemicals, Materials, Industrial Solutions, Nutrition & Care) that stay integrated, and standalone businesses (Agricultural Solutions, Battery Materials, Environmental Catalyst and Metal Solutions, and the now-divested Coatings) that are being monetized or prepared for capital-market options. In 2025 it generated €59.7 billion in sales and €6.6 billion in EBITDA before special items, a cyclical trough. In 2026 it closed the €7.7 billion Coatings transaction, started up its €-multi-billion Zhanjiang Verbund site, raised earnings guidance, and approached Evonik about a takeover. The investment debate is whether structural cost cuts and portfolio proceeds can restore returns above the cost of capital. --- **The company's own description.** BASF describes its purpose with the line "we create chemistry for a sustainable future" (BASF news release boilerplate, 2026) and states its ambition to be the preferred chemical company for enabling customers' green transformation. It reports around 108,000 employees, customers in nearly every sector and almost every country, and sales of around €60 billion in 2025. The portfolio is described as four core segments plus standalone businesses bundled in Surface Technologies and Agricultural Solutions. **Independent characterization.** BASF is best understood as three businesses under one roof: 1. **An integrated commodity and intermediates engine** (Chemicals, the Monomers half of Materials). This is a steam-cracker-to-derivatives chain selling ethylene and propylene derivatives, isocyanates, polyamide precursors and intermediates on spread economics. Earnings are driven by feedstock and energy costs, operating rates and regional supply-demand. It is the most capital-intensive part of the group and the main source of the 2023–2025 earnings decline: Chemicals EBITDA before special items fell from €1,342 million in 2024 to €853 million in 2025 (Factsheet FY2025). 2. **Formulated and performance products** (Performance Materials, Industrial Solutions, Nutrition & Care). These sell on specification and performance to automotive, construction, packaging, consumer goods, pharma and nutrition customers. Margins are steadier but have come under pressure from Asian competition and, in Care Chemicals, from consumer trading-down to private-label products (Factsheet FY2025 commentary). 3. **Standalone franchises** with different industry logic: Agricultural Solutions (crop protection, seeds and traits, digital farming), ECMS (emissions catalysts plus precious-metal trading and recycling) and Battery Materials. Agricultural Solutions is the group's highest-margin segment at 21.7% EBITDA margin before special items in FY2025 and the largest single earnings contributor at €2,081 million. **Revenue model.** Revenue is almost entirely product sales under supply contracts and spot transactions. There is no subscription model of consequence; digital farming (xarvio) and licensing of process technology and catalysts are small. Seeds and traits include royalty and licensing income within Agricultural Solutions, not separately disclosed. Precious-metal trading inflates ECMS sales (€7,978 million in FY2025) with pass-through metal value, which is why BASF quotes group margins both including and excluding metals (12.3% excluding metals in FY2025 per the CFO on the February 27, 2026 call, versus 11.0% reported). **Value chain position.** Upstream to midstream in petrochemicals with captive crackers at Ludwigshafen, Antwerp, Port Arthur (joint venture with TotalEnergies), Nanjing (joint venture with Sinopec) and Zhanjiang; midstream to downstream in engineering plastics, polyurethane systems, dispersions, additives, surfactants and vitamins; branded and channel-driven in agriculture. BASF exited upstream oil and gas operations when Wintershall Dea's E&P business was transferred to Harbour Energy in September 2024. **Customers and end-markets.** BASF serves industrial customers in chemicals and plastics, transportation, construction, consumer goods, agriculture, electronics, energy and resources, and health and nutrition. Intersegment transfers are large (Chemicals transferred €3,432 million internally in FY2025 on €10,055 million of third-party sales), which shows how much of the upstream output feeds BASF's own downstream chains.
Bayer is a German life-science group with three businesses: Crop Science, Pharmaceuticals and Consumer Health. It is the world's largest combined seed, trait and crop-protection supplier, a mid-sized prescription-drug maker, and a top-five self-care company. Fiscal 2025 sales were EUR 45.6 billion. The 2018 purchase of Monsanto brought leading corn and soybean genetics but also glyphosate and PCB litigation, which has consumed well over EUR 10 billion in settlements and produced net losses in 2023, 2024 and 2025. Under CEO Bill Anderson the company has cut management layers, held the dividend at the legal minimum, and concentrated on four priorities: rebuilding the pharma pipeline, containing litigation, reducing debt and improving crop profitability. In 2026 a 7–2 U.S. Supreme Court ruling on federal pre-emption and a proposed USD 7.25 billion class settlement moved the litigation closer to resolution, though the settlement still awaits final court approval. --- **Company's own description.** Bayer describes itself as a global enterprise with core competencies in the life-science fields of health care and nutrition, operating under the mission "Health for all, Hunger for none" (Annual Report 2025; press boilerplate 2026). Bayer AG is a holding company; operations sit in subsidiaries worldwide. In fiscal 2025 the Group had about 88,000 employees, sales of EUR 45.6 billion and R&D expenses of EUR 5.8 billion. **Independent characterisation.** Bayer is best understood as three distinct businesses sharing a balance sheet, a brand and a legal liability. Crop Science (47 percent of FY2025 sales) is an input supplier to farmers. It earns money from proprietary seed and biotech traits, from chemical and biological crop protection, and to a small extent from digital farming subscriptions. Seed and trait revenue carries royalty-like economics: Bayer licenses traits to other seed companies, and two licensing settlements with Corteva lifted results in Q4 2025 and Q1 2026. The business is strongly seasonal, with Northern Hemisphere sales concentrated in the first half and Latin American sales in the second. Pharmaceuticals (39 percent of sales) discovers, develops and sells prescription medicines, concentrated in cardiovascular and renal disease, oncology, women's health and ophthalmology, plus a radiology unit selling contrast agents and injector hardware. Revenue is almost entirely product sales, with some licence income (for example U.S. Xarelto royalties from Johnson & Johnson, and Eylea outside the United States under a collaboration with Regeneron). The division is in the middle of a patent transition: Xarelto and Eylea are declining while Nubeqa and Kerendia are growing quickly. Consumer Health (13 percent of sales) sells non-prescription brands through pharmacies, mass retail and e-commerce. It is a branded consumer-goods model with stable margins and low capital intensity. **Revenue model mix.** Bayer does not disclose a product/service/licensing split. On the evidence of the Annual Report 2025, the large majority of revenue is product sales; licensing income is embedded in Crop Science seed and trait lines and in Pharmaceuticals; subscription revenue (Climate FieldView, radiology software) is immaterial at Group level. An exact percentage split is not publicly disclosed. **Value-chain position.** Bayer is a research-based originator and manufacturer. It owns discovery, development, active-ingredient and finished-product manufacturing, and commercial organisations, and sells through distributors, retailers, wholesalers, hospitals and pharmacies rather than directly to end users in most markets. **Customers and end markets.** Farmers, agricultural retailers and distributors, and seed licensees (Crop Science); wholesalers, hospitals, physicians, pharmacy chains, governments and payers (Pharmaceuticals); pharmacies, supermarkets, drugstores and online retailers (Consumer Health).
4 interactive charts drawn from the Bacillus Firmus Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Bacillus Firmus Market By Application Method
Global Bacillus Firmus Market By Crop Type
Global Bacillus Firmus Market By Formulation
Global Bacillus Firmus Market By Region
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
